<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323867</url>
  </required_header>
  <id_info>
    <org_study_id>13-010495</org_study_id>
    <secondary_id>BT13BTθ51</secondary_id>
    <nct_id>NCT02323867</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies</brief_title>
  <acronym>AB-CliniMACs</acronym>
  <official_title>UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm pilot study for patients using α/β T cell-depleted PSCT in with
      alternative donor sources with hematologic malignancies receiving alternative donor
      (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the
      CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as
      determined by engraftment and GVHD, and one year leukemia free survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>intervention with device: Alpha Beta T cell depletion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment: rates of engraftment, defined as the first day of Absolute Neutrophil Count (ANC) greater than 500 for the first of three consecutive days</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe acute and chronic graft versus host disease (GVHD)</measure>
    <time_frame>1 year</time_frame>
    <description>Estimation of the incidence and extent of acute and chronic GVHD. The overall incidence of acute GVHD, the incidence of Grade 4 acute GVHD and the incidence of chronic GVHD.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>Alpha Beta Total Body Irradiation - TBI first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha Beta Total Body Irradiation - TBI first Day Treatment
8 TBI
7 TBI
6 TBI
5 Thiotepa &amp; ATG
4 Thiotepa &amp; ATG
3 Cyclophosphamide &amp; ATG
2 Cyclophosphamide
1 Rest 0 Transplant with alpha beta T cell depleted stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha Beta Total Body Irradiation - TBI last</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha Beta Total Body Irradiation - TBI last Day Treatment
7 Thiotepa
6 Thiotepa
5 Cyclophosphamide &amp; ATG
4 Cyclophosphamide &amp; ATG
3 TBI &amp; &amp; ATG
2 TBI
1 TBI 0 Transplant with alpha beta T cell depleted stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha Beta Non-irradiation regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha Beta Non-irradiation regimen Day Treatment
9 Busulfan
8 Busulfan
7 Busulfan
6 Busulfan
5 Thiotepa &amp; ATG
4 Thiotepa &amp; ATG
3 Cyclophosphamide &amp; ATG
2 Cyclophosphamide
1 0 Transplant with alpha beta T cell depleted stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alpha Beta T cell depletion</intervention_name>
    <arm_group_label>Alpha Beta Total Body Irradiation - TBI first</arm_group_label>
    <arm_group_label>Alpha Beta Total Body Irradiation - TBI last</arm_group_label>
    <arm_group_label>Alpha Beta Non-irradiation regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Leukemias/lymphomas

               -  Acute myeloid leukemia, primary or secondary Disease status: remission or &lt;10%
                  bone marrow blasts

               -  Myelodysplasia

               -  Acute lymphoblastic leukemia Disease status: in hematologic remission

               -  Chronic myelogenous leukemia Disease status: chronic phase, accelerated phase or
                  blast crisis now in second chronic phase.

               -  Mixed lineage or biphenotypic acute leukemia

               -  Lymphoblastic lymphoma Disease status: remission

               -  Burkitt's lymphoma/leukemia: Disease status- in remission

          2. Acceptable organ status clearance

          3. No active untreated infection. Patients with possible fungal infections must have had
             at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic

          4. Signed informed consent.

          5. Negative pregnancy test for females of childbearing potential.

        Exclusion Criteria:

          1. Patients who do not meet disease, organ or infectious criteria.

          2. No suitable donor

        Donor must be either unrelated, mismatched up to one antigen/one antigen and one allele or
        a related, HLA match other than a sibling.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Bunin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Tartaglione, RN</last_name>
    <phone>215-590-4029</phone>
    <email>tartaglione@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Hankins, RN</last_name>
    <phone>215-590-4029</phone>
    <email>hankinsp@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Tartaglione, RN</last_name>
      <phone>215-590-4029</phone>
      <email>tartaglione@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Hankins, RN</last_name>
      <phone>215-590-5168</phone>
      <email>hankinsp@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nancy J Bunin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan A Grupp, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Nancy Bunin</investigator_full_name>
    <investigator_title>Director, Blood and Marrow Transplant</investigator_title>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>Alternative Donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

